IDEMIA
16.6.2021 13:32:04 CEST | Business Wire | Press release
The Project Embarque + Seguro 100% Digital Boarding System, using the Brazilian government’s facial recognition, arrives this Tuesday (June 15) at the Congonhas Airport (SP). For the first time in the world, passengers on the air shuttle service between the capitals of São Paulo and Rio de Janeiro will participate in the simultaneous testing of this end-to-end technology without the need to present neither a boarding pass nor an identification document. The Project of the Ministry of Infrastructure, developed in partnership with Serpro and the Special Secretariat of Debureaucratization, Management and Digital Government of the Ministry of Economy, has already been tested at the airports of Florianópolis (SC), Salvador (BA), Santos Dumont (RJ) and Belo Horizonte (Confins).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005505/en/
After the approval of the pilot project, the Federal Government will move forward with actions to effectively implement the technology in major Brazilian airports. The technology aims at making the boarding process at airports more efficient, agile, and secure. "It is the first time that tests are carried out simultaneously in two of our airports, thus establishing, in an unprecedented way, a 100% biometric air shuttle between RJ / SP, which has the fifth-largest movement in the world", highlights the executive secretary of MInfra, Marcelo Sampaio.
Throughout the day, Azul Linhas Aéreas’s passengers travelling between Congonhas and Santos Dumont airports will be invited to try the biometric facial recognition technology to access both boarding area and aircraft at both terminals. "Embarque + Seguro combines biometric validation and data analysis, ensuring an accurate, agile and secure validation of the identity of passengers, who can thus travel with more comfort and tranquility. The solution complies with the General Data Protection Law (LGPD) and is premised on security in the processing of personal data against misuse or unauthorized use", emphasizes the president of Serpro, Gileno Barreto.
For the president of Infraero, Brigadier Paes de Barros, "the air shuttle’s Embarque + Seguro unites two essential items that streamline the boarding processes, which are safety and ease for the passenger and the entire civil aviation system".
According to the Director of Public Security & Identity (PSI) of IDEMIA in Brazil, Márcio Lambert, "Facial recognition is a global trend and the Project Embarque + Seguro, jointly carried out by Minfra and Serpro, shows that Brazil is on the right track to airport digitalization. IDEMIA’s technology is applied in the most modern airports around the world, such as Changi in Singapore, and offers a high level of security for passengers, airlines, and airport operators, as its algorithm is highly accurate, reaching a extremely high authenticity rate in the identification of individuals. IDEMIA is proud to participate in this project along with Brazil’s Federal Government and to enable the world’s first 100% end-to-end digitized boarding system in an executive air shuttle service".
"The latest Global Passengers Research conducted by the International Air Transport Association (IATA) says that 70% of interviewees are willing to share their biometry for identification purposes during the boarding process. Our global expertise contributes to meeting society’s need to fly again. This innovative project developed by the Federal Government allows travelers to enjoy a quieter, safer and more comfortable boarding experience and puts Brazil at the forefront of the digital transformation movement. IDEMIA as a global leader in augmented identity has the mission to facilitate the flow of passengers by creating the possibility to interact and travel in a more connected way. To participate in the first air shuttle with an end-to-end fully digitized boarding system, in both airports, is an important milestone in our history,” explains Rodrigo Costa, PSI business development director at IDEMIA LATAM.
The MFACE technology, developed by IDEMIA, captures facial biometrics in seconds, making the boarding process even more agile, avoiding queues and delays. The solution combines the convenience and security of data validation, respecting the privacy of passengers according to the GDPR, and ensures a more hygienic process by eliminating document and paper handling, thus avoiding the risk of contamination.
"The control of IDEMIA’s biometric system follows high-quality, reliability and safety standards and offers more agility and comfort to passengers, turning the airport operational process more intelligent, the airline passenger identification more accurate, and generates the security required by the government," adds Márcio Lambert.
How it works
When checking in at the airport, the passenger of Azul Linhas Aéreas is invited to participate in the project. If the passenger agrees, then a message is sent to the cell phone informed in the application, requesting authorization to obtain the passenger’s data, including the social security number and a photo. Upon consent, the airline attendant, using the application developed by Serpro for this purpose, performs the biometric validation of the citizen, comparing the data and the photo taken on the spot with the government databases.
After validated, the passenger is released to enter the departure hall and the aircraft passing through biometric control points, whose cameras perform the passenger’s identification without the need for the user to present any document or boarding pass.
Total Security
In the pilot project, indicators such as queue time reduction, access to the departure hall and aircraft are measured, in addition to operating costs. With the tests, it is expected that airport security increases, as facial recognition allows an accurate identification of passengers.
"We are moving towards a fully secure biometric boarding at every airport in the country. In addition to the process being safe from the sanitary point of view, by eliminating the handling of papers during the pandemic, it guarantees the total protection of users' data, because the Embarque + Seguro 100% Digital Boarding System meets all the precepts of the LGPD", says Marcelo Sampaio.
Partnerships
Serpro is MInfra’s strategic partner in the country's transportation digital agenda, but Embarque + Seguro also has the collaboration of airlines and airports where the tests have been carried out, which has enabled the improvement of the project at each stage. The air shuttle pilot test is being implemented with the support of Infraero and Azul Linhas Aéreas; and the technology of facial identification stations was developed by Digicon, IDEMIA and Azul/Pacer companies.
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated, and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com
/ Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
